A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- GlaxoSmithKline
- Study ID
- NCT01128894
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- albiglutide — BIOLOGICALalbiglutide weekly subcutaneous injection
- liraglutide — DRUGliraglutide daily subcutaneous injection, starting at 0.6mg, then up-titrating to 1.2mg then 1.8mg in accordance with prescribing information.
Study Details
This open-label study examines the efficacy and safety of albiglutide as compared with liraglutide in subjects with type 2 diabetes.
Key Dates
- Start date
- May 31, 2010
- Status verified
- Jan 2017
- Primary completion
- Sep 30, 2011
- Completion
- Sep 30, 2011
Study Design
- Enrollment
- 841 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: albiglutideweekly albiglutide subcutaneous injection
- Active Comparator: liraglutideliraglutide daily subcutaneous injection, starting at 0.6mg, then up-titrating to 1.2mg then 1.8mg in accordance with prescribing information.
Primary Outcome Measure
Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 32 [ Time Frame: Baseline and Week 32 ]
Locations (129)
Find similar trials in Birmingham, AL
By condition
By specialty
Related Studies
- Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)Recruiting · The University of Texas Health Science Center at San Antonio · San Antonio, Texas
- Tau PET Imaging in the Northern Manhattan Study of Metabolism and Mind.PHASE2 · Enrolling By Invitation · Columbia University · New York, New York
- Blood Markers of Early Pancreas CancerRecruiting · University of Nebraska · Omaha, Nebraska
- Phenotyping Genetic Risk for Type 2 DiabetesRecruiting · University of Pennsylvania · Philadelphia, Pennsylvania